FLT3
EstablishedFLT3-ITD is a common AML mutation central to risk stratification and eligibility for FLT3-targeted drugs (midostaurin, gilteritinib).
FLT3 is a growth-signaling protein, and one type of mutation in it is very common in AML, a type of blood cancer. This mutation now has its own targeted drugs, and newly updated 2024 guidelines show it can dramatically worsen the outlook even in AML types that are otherwise considered favorable, directly shaping how aggressively doctors treat a given patient.
FLT3 (FMS-like tyrosine kinase 3) is a receptor tyrosine kinase important in normal blood cell development; internal tandem duplication mutations (FLT3-ITD) are among the most common genetic abnormalities in acute myeloid leukemia (AML), found in roughly 30% of cases.
FLT3-ITD status is central to AML risk stratification and directly determines eligibility for FLT3-targeted therapy; per the newly updated 2024 European LeukemiaNet (ELN) recommendations for less-intensive therapy, FLT3-ITD is now classified as intermediate risk (alongside NRAS/KRAS mutations), while co-occurring FLT3-ITD substantially worsens the otherwise favorable prognosis of NPM1-mutated AML.
Detected via PCR-based fragment analysis or NGS panel on bone marrow or blood; testing must specifically assess for internal tandem duplications, which standard sequencing approaches can sometimes miss depending on assay design.
FLT3 inhibitors (midostaurin, added to induction chemotherapy; gilteritinib, used in relapsed/refractory disease) are now standard of care for FLT3-mutated AML, representing one of the first targeted therapy successes in AML beyond APL; the 2024 ELN data specifically show that co-occurring FLT3-ITD substantially worsens NPM1-mutated AML's normally favorable prognosis (median survival dropping from 39 to under 10 months in one analysis), directly affecting treatment intensity decisions.
The newly updated 2024 ELN risk classification shows FLT3-ITD substantially worsens otherwise-favorable NPM1-mutated AML prognosis.
- Hematology Advisor. (2024). New AML Prognostic Model Proposed in 2024 ELN Recommendations.
- Blood. (2024). Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.